Molecular hydrogen is a potent therapeutic agent with documented antioxidant, anti-inflammatory, and cytoprotective properties. Its small size allows it to easily penetrate cells and tissues to exert therapeutic effects at a cellular level. This targeted action helps to reduce oxidative stress, which is a major contributor to inflammation and tissue damage in respiratory diseases. The document explains that H₂ selectively neutralizes harmful reactive oxygen species (ROS) without affecting the beneficial ones needed for cell signaling.

How Can H₂ Therapy Help Respiratory Patients?

The document highlights how molecular hydrogen therapy can be a valuable tool in the management of several respiratory conditions:

●       Asthma: The pathophysiology of asthma involves airway inflammation, and the paper explains that H₂'s anti-inflammatory properties can help address this issue.

●       Chronic Obstructive Pulmonary Disease (COPD): COPD is a leading cause of death worldwide and is characterized by chronic inflammation. The document notes that H₂ therapy's ability to reduce inflammation makes it a promising option for managing COPD.

●       Chronic Bronchitis: As a form of COPD, chronic bronchitis involves a productive cough and inflammation. The anti-inflammatory effects of H₂ can be beneficial in addressing this condition.